Clinically, ADCC strategy has been used in CD20+ lymphoma patients treated with rituximab (RituxanTM) (17) or HER2/neu-expressing breast cancer patients treated with trastuzumab (HerceptinTM) (18). Here, ERBB2 is linked to lymphoma.